{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:04:42Z","timestamp":1792267482689,"version":"4.4.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computer Methods and Programs in Biomedicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.cmpb.2025.108919","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:34:45Z","timestamp":1751373285000},"page":"108919","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Pharmacometric and Digital Twin modeling for adaptive scheduling of combination therapy in advanced gastric cancer"],"prefix":"10.1016","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7601-4212","authenticated-orcid":false,"given":"Michela","family":"Prunella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-4968","authenticated-orcid":false,"given":"Nicola","family":"Altini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"D\u2019Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Schirizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0701-6764","authenticated-orcid":false,"given":"Angela Dalia","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Lotesoriere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4009-3534","authenticated-orcid":false,"given":"Paolo","family":"Scarabaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Carli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1459-3452","authenticated-orcid":false,"given":"Mariagrazia","family":"Dotoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Giannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3088-0788","authenticated-orcid":false,"given":"Vitoantonio","family":"Bevilacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmpb.2025.108919_b1","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211042812","article-title":"Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)","volume":"13","author":"Han","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.cmpb.2025.108919_b2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/sj.neo.7900038","article-title":"The role of the vascular phase in solid tumor growth: a historical review","volume":"1 4","author":"Ribatti","year":"1999","journal-title":"Neoplasia"},{"key":"10.1016\/j.cmpb.2025.108919_b3","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.cmpb.2025.108919_b4","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41416-021-01330-z","article-title":"Vascular normalisation as the stepping stone into tumour microenvironment transformation","volume":"125","author":"Magnussen","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cmpb.2025.108919_b5","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-019-1063-4","article-title":"Prognostic value of microvessel density in stage II and III colon cancer patients: a retrospective cohort study","volume":"19","author":"den Uil","year":"2019","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.cmpb.2025.108919_b6","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1158\/1535-7163.MCT-08-0715","article-title":"Combination of antiangiogenesis with chemotherapy for more effective cancer treatment","volume":"7","author":"Ma","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cmpb.2025.108919_b7","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1038\/s12276-023-01114-w","article-title":"Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy","volume":"55","author":"Choi","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.cmpb.2025.108919_b8","first-page":"529","article-title":"Antiangiogenic therapy: creating a unique \u201dwindow\u201d of opportunity","volume":"6 6","author":"Lin","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cmpb.2025.108919_b9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.cmpb.2025.108919_b10","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/jso.26844","article-title":"Advances in screening and detection of gastric cancer","volume":"125","author":"Xia","year":"2022","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.cmpb.2025.108919_b11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cmpb.2025.108919_b12","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15 11","author":"Wilke","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cmpb.2025.108919_b13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1261312","article-title":"Optimizing dose-schedule regimens with bayesian adaptive designs: opportunities and challenges","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cmpb.2025.108919_b14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.18475","article-title":"Effect of Bevacizumab in combination with standard oxaliplatin-based regimens in patients with metastatic colorectal cancer","volume":"4","author":"Avallone","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.cmpb.2025.108919_b15","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers","volume":"31 17","author":"Jain","year":"2013","journal-title":"J. Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.cmpb.2025.108919_b16","article-title":"Liquid biopsy of lung cancer before pathological diagnosis is associated with shorter time to treatment","volume":"8","author":"Russo","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.cmpb.2025.108919_b17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s43018-020-00163-8","article-title":"Envisioning the future of precision oncology trials","volume":"2","author":"Madhavan","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.cmpb.2025.108919_b18","first-page":"236","article-title":"Virtual clinical trials: A tool for predicting patients who may benefit from treatment beyond progression with pembrolizumab in non-small cell lung cancer","volume":"12","author":"Qi","year":"2022","journal-title":"CPT: Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.cmpb.2025.108919_b19","doi-asserted-by":"crossref","DOI":"10.1016\/j.landig.2025.01.007","article-title":"Digital twins, synthetic patient data, and in-silico trials: can they empower paediatric clinical trials?","author":"Pammi","year":"2025","journal-title":"Lancet Digit. Heal."},{"key":"10.1016\/j.cmpb.2025.108919_b20","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s43588-022-00377-z","article-title":"Mathematical modeling of cancer immunotherapy for personalized clinical translation","volume":"2 12","author":"Butner","year":"2022","journal-title":"Nat. Comput. Sci."},{"key":"10.1016\/j.cmpb.2025.108919_b21","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cell.2015.11.002","article-title":"Improving cancer treatment via mathematical modeling: Surmounting the challenges is worth the effort","volume":"163","author":"Michor","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.cmpb.2025.108919_b22","article-title":"Phys-DAT: A physiologically-based pharmacokinetic model for unraveling the dissolution, transit and absorption processes using PhysPK\u00ae","volume":"243","author":"Cuquerella-Gilabert","year":"2023","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.cmpb.2025.108919_b23","first-page":"691","article-title":"On the optimality of singular controls for a class of mathematical models for tumor anti-angiogenesis","volume":"11","author":"Ledzewicz","year":"2009","journal-title":"Discrete Contin. Dyn. Syst. Ser. B"},{"key":"10.1016\/j.cmpb.2025.108919_b24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.compbiomed.2019.04.011","article-title":"Derivation of an optimal trajectory and nonlinear adaptive controller design for drug delivery in cancerous tumor chemotherapy","volume":"109","author":"Khalili","year":"2019","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.cmpb.2025.108919_b25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bspc.2019.101639","article-title":"A comparison between Nonlinear Least Squares and Maximum Likelihood estimation for the prediction of tumor growth on experimental data of human and rat origin","volume":"54","author":"Patmanidis","year":"2019","journal-title":"Biomed. Signal Process. Control."},{"key":"10.1016\/j.cmpb.2025.108919_b26","article-title":"Optimal control design for drug delivery of immunotherapy in chemoimmunotherapy treatment","volume":"229","author":"Khalili","year":"2022","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.cmpb.2025.108919_b27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bspc.2018.09.016","article-title":"Cancer therapy optimization based on multiple model adaptive control","volume":"48","author":"Teles","year":"2019","journal-title":"Biomed. Signal Process. Control."},{"key":"10.1016\/j.cmpb.2025.108919_b28","doi-asserted-by":"crossref","DOI":"10.1038\/s41540-024-00461-2","article-title":"A mathematical framework for comparison of intermittent versus continuous adaptive chemotherapy dosing in cancer","volume":"10","author":"Mcgehee","year":"2024","journal-title":"NPJ Syst. Biol. Appl."},{"key":"10.1016\/j.cmpb.2025.108919_b29","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1158\/0008-5472.CAN-03-2524","article-title":"Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents","volume":"64","author":"Simeoni","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.cmpb.2025.108919_b30","first-page":"591","article-title":"New approach to modeling of antiangiogenic treatment on the basis of Hahnfeldt et al. model","volume":"8 2","author":"Poleszczuk","year":"2011","journal-title":"Math. Biosci. Eng. : MBE"},{"key":"10.1016\/j.cmpb.2025.108919_b31","first-page":"4770","article-title":"Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy","volume":"59 19","author":"Hahnfeldt","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.cmpb.2025.108919_b32","unstructured":"B.P. Gompertz, XXIV. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. In a letter to Francis Baily, Esq. F. R. S. &c, Philos. Trans. R. Soc. Lond. 513\u2013583."},{"key":"10.1016\/j.cmpb.2025.108919_b33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.crma.2011.11.019","article-title":"A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology","volume":"350","author":"Benzekry","year":"2012","journal-title":"C. R. Math."},{"key":"10.1016\/j.cmpb.2025.108919_b34","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11102721","article-title":"VEGFA status as a predictive marker of therapy outcome in metastatic gastric cancer patients following ramucirumab-based treatment","volume":"11","author":"Schirizzi","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.cmpb.2025.108919_b35","first-page":"317","article-title":"Logistic equations in tumour growth modelling","volume":"13","author":"Fory\u015b","year":"2003","journal-title":"Int. J. Appl. Math. Comput. Sci."},{"key":"10.1016\/j.cmpb.2025.108919_b36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.867098","article-title":"Escaping death: How cancer cells and infected cells resist cell-mediated cytotoxicity","volume":"13","author":"Tuomela","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cmpb.2025.108919_b37","doi-asserted-by":"crossref","unstructured":"G. Bredholt, M. Mannelqvist, I.M. Stefansson, E. Birkeland, T. Hellem B\u00f8, et al., Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses, Oncotarget (ISSN: 1949-2553) 6 (37).","DOI":"10.18632\/oncotarget.5344"},{"key":"10.1016\/j.cmpb.2025.108919_b38","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45 2","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cmpb.2025.108919_b39","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-14-1429","article-title":"Translational implications of tumor heterogeneity","volume":"21","author":"Jamal-Hanjani","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.cmpb.2025.108919_b40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1006\/jtbi.2000.1075","article-title":"A dynamical model for the growth and size distribution of multiple metastatic tumors","volume":"203","author":"Iwata","year":"2000","journal-title":"J. Theoret. Biol."},{"issue":"5","key":"10.1016\/j.cmpb.2025.108919_b41","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1200\/JOP.2014.001457","article-title":"Simple prognostic model for patients with advanced cancer based on performance status","volume":"10","author":"Jang","year":"2014","journal-title":"J. Oncol. Pr."},{"issue":"4","key":"10.1016\/j.cmpb.2025.108919_b42","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000862","article-title":"A decision-tree approach to stratify DLBCL risk based on stromal and immune microenvironment determinants","volume":"7","author":"Zaccaria","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.cmpb.2025.108919_b43","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2023.107966","article-title":"SurvIAE: survival prediction with interpretable autoencoders from diffuse large B-Cells lymphoma gene expression data","volume":"244","author":"Zaccaria","year":"2024","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.cmpb.2025.108919_b44","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1007\/s11538-019-00640-x","article-title":"Mathematical models of cancer: When to predict novel therapies, and when not to","volume":"81","author":"Brady","year":"2019","journal-title":"Bull. Math. Biol."},{"key":"10.1016\/j.cmpb.2025.108919_b45","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1158\/1078-0432.CCR-15-0600","article-title":"FDA approval summary: Ramucirumab for gastric cancer","volume":"21","author":"Casak","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cmpb.2025.108919_b46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120007","article-title":"Therapeutic implications from sensitivity analysis of tumor angiogenesis models","volume":"10","author":"Poleszczuk","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cmpb.2025.108919_b47","unstructured":"M. Prunella, N. Altini, G.M. Zaccaria, P. Scarabaggio, R. Carli, M. Dotoli, V. Bevilacqua, Pharmacokinetic-pharmacodynamic modeling of tumor angiogenesis unveils the need for time-adjustable drug regimens, in: Proceedings of the IX Congress of the National Group of Bioengineering, GNB, Palermo, Italy, 2025, June 16\u201318."},{"key":"10.1016\/j.cmpb.2025.108919_b48","article-title":"Oncology phase I trial design and conduct: Time for a change MDICT guidelines 2022","author":"Araujo","year":"2022","journal-title":"Ann. Oncol. : Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.cmpb.2025.108919_b49","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/SLA.0b013e3181d3d29b","article-title":"Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram","volume":"251","author":"Strong","year":"2010","journal-title":"Ann. Surg."},{"key":"10.1016\/j.cmpb.2025.108919_b50","doi-asserted-by":"crossref","first-page":"23087","DOI":"10.18632\/oncotarget.15484","article-title":"Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis","volume":"8","author":"Mollard","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cmpb.2025.108919_b51","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/00401706.1987.10488205","article-title":"Large sample properties of simulations using latin hypercube sampling","volume":"29","author":"Stein","year":"1987","journal-title":"Technometrics"},{"key":"10.1016\/j.cmpb.2025.108919_b52","series-title":"WebPlotDigitizer, a polyvalent and free software to extract spectra from old astronomical publications: application to ultraviolet spectropolarimetry","author":"Marin","year":"2017"}],"container-title":["Computer Methods and Programs in Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169260725003360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169260725003360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:15:12Z","timestamp":1756311312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169260725003360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":52,"alternative-id":["S0169260725003360"],"URL":"https:\/\/doi.org\/10.1016\/j.cmpb.2025.108919","relation":{},"ISSN":["0169-2607"],"issn-type":[{"value":"0169-2607","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacometric and Digital Twin modeling for adaptive scheduling of combination therapy in advanced gastric cancer","name":"articletitle","label":"Article Title"},{"value":"Computer Methods and Programs in Biomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmpb.2025.108919","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108919"}}